 |
| |
| Mar-13-20 | Upgrade |
Macquarie |
Underperform → Neutral |
|
|
| Feb-18-20 | Resumed |
Goldman |
Buy |
|
|
| Jan-17-20 | Upgrade |
CLSA |
Outperform → Buy |
|
|
| Jan-17-20 | Resumed |
Morgan Stanley |
Overweight |
$210 |
|
| Dec-16-19 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| Dec-16-19 | Downgrade |
Guggenheim |
Buy → Neutral |
|
|
| Nov-19-19 | Downgrade |
UBS |
Buy → Neutral |
|
|
| Nov-13-19 | Downgrade |
CLSA |
Buy → Outperform |
|
|
| Nov-04-19 | Reiterated |
Maxim Group |
Buy |
$170 → $210 |
|
| Jun-04-19 | Initiated |
Bernstein |
Outperform |
$201 |
|
| May-10-19 | Upgrade |
CLSA |
Outperform → Buy |
|
|
| Mar-15-19 | Initiated |
BofA/Merrill |
Buy |
$200 |
|
| Jan-04-19 | Downgrade |
CLSA |
Buy → Outperform |
|
|
| Nov-21-18 | Initiated |
JP Morgan |
Overweight |
$174 |
|
| Sep-25-18 | Initiated |
Leerink Partners |
Outperform |
|
|
| May-17-18 | Reiterated |
Maxim Group |
Buy |
$200 → $225 |
|
| May-14-18 | Initiated |
Credit Suisse |
Outperform |
|
|
| Apr-13-18 | Initiated |
Piper Jaffray |
Overweight |
$200 |
|
| Apr-10-18 | Reiterated |
Maxim Group |
Buy |
$160 → $200 |
|
| Mar-01-18 | Reiterated |
Maxim Group |
Buy |
$144 → $160 |
|
|
|
| Mar-26-20 02:30PM | ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. Business Wire |
| Mar-25-20 09:00AM | BeiGene Announces Supply Update for ABRAXANE® in China GlobeNewswire -5.75% |
| Mar-19-20 05:09PM | Hedge Funds Are Betting On BeiGene, Ltd. (BGNE) Insider Monkey |
| Mar-10-20 12:57PM | INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire |
| Mar-09-20 12:30PM | ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| Mar-07-20 10:31AM | Coronavirus Outbreak Could Disrupt Drug Companies Clinical Trials Barrons.com |
| Mar-02-20 04:05PM | BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire |
| Feb-27-20 07:14AM | MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors GlobeNewswire |
| Feb-25-20 07:00AM | BeiGene to Present at the Cowen and Companys 40th Annual Health Care Conference GlobeNewswire |
| Feb-18-20 10:49AM | Amgen Inc. -- Moody's assigns Baa1 rating to Amgen's new sr. unsecured notes; stable outlook Moody's |
| Jan-21-20 07:00AM | BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis GlobeNewswire |
| Jan-13-20 07:00AM | EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA® in Greater China GlobeNewswire |
| Jan-08-20 07:30AM | BeiGene to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire |
| Jan-06-20 08:25AM | Leap Therapeutics Surges on License Agreement With BieGene Zacks |
| Jan-03-20 02:11PM | Cash-strapped biotech signs deal with Chinese drugmaker BeiGene American City Business Journals |
| 08:53AM | Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing PR Newswire |
| Jan-02-20 08:15AM | BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment GlobeNewswire |
| Dec-30-19 05:17PM | BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China Zacks |
| Dec-28-19 09:30AM | ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| Dec-27-19 10:30PM | China National Medical Products Administration Approves BeiGenes Tislelizumab for Patients with Classical Hodgkins Lymphoma Who Have Received at Least Two Prior Therapies GlobeNewswire |
| Dec-22-19 06:00PM | BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma GlobeNewswire |
| Dec-20-19 09:25AM | Key AbbVie Drug Faces Competition Worries After Head-to-Head Study Barrons.com |
| Dec-19-19 04:40PM | These Hedge Funds Cashed Out Of BeiGene, Ltd. (BGNE) Too Early Insider Monkey |
| Dec-16-19 07:00AM | BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenströms Macroglobulinemia GlobeNewswire -6.21% |
| Dec-13-19 07:00AM | BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019 GlobeNewswire |
| Dec-08-19 04:45PM | BeiGene Announces Clinical Data on BRUKINSA (Zanubrutinib) at the 61st American Society of Hematology (ASH) Annual Meeting GlobeNewswire |
| Dec-02-19 06:02PM | SK Biopharmaceuticals IPO Tabbed to Raise $850 Million GuruFocus.com |
| Nov-29-19 03:30PM | BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| Nov-26-19 05:54PM | BeiGene Shares Climb Nearly 50% After Amgen Deal GuruFocus.com |
| 07:00AM | BeiGene to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire |
| Nov-23-19 05:00AM | BeiGene Announces Clinical Data on Tislelizumab Presented at European Society for Medical Oncology (ESMO) Asia 2019 Congress GlobeNewswire |
| Nov-16-19 08:43AM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE |
| Nov-15-19 05:34PM | BeiGene prices lymphoma drug at $12,935 for a 30-day supply Reuters |
| 10:09AM | The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga |
| 04:30AM | Stocks Blog: AAC Technologies, BeiGene jump; Hang Seng Index rises as traders look for bargains South China Morning Post |
| 02:00AM | US regulator issues first approval for a Chinese cancer treatment Financial Times |
| Nov-14-19 04:20PM | U.S. FDA Grants BeiGenes BRUKINSA (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy GlobeNewswire |
| 04:01PM | UPDATE 2-China's BeiGene gets FDA approval for drug to treat rare form of lymphoma Reuters |
| 03:49PM | BeiGene drug wins U.S. FDA approval for rare form of lymphoma Reuters |
| Nov-13-19 03:11PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire |
| Nov-12-19 04:05PM | BeiGene Reports Third Quarter 2019 Financial Results GlobeNewswire |
| Nov-11-19 06:30PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE |
| Nov-10-19 07:00PM | ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| Nov-07-19 05:54PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE GlobeNewswire |
| Nov-06-19 10:58AM | Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire |
| 09:00AM | BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 61st American Society of Hematology Annual Meeting GlobeNewswire |
| Nov-05-19 10:13AM | The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill Zacks |
| 08:00AM | Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate Business Wire |
| Nov-04-19 11:18AM | AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates Zacks |
| 07:56AM | 4 Stocks to Buy From Sectors With Maximum Job Gains Zacks |
| Nov-01-19 06:12PM | BEIGENE ALERT: Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire +37.02% |
| 03:18PM | Biotech ETFs Strengthen as Amgen Invests in Chinas BeiGene ETF Trends |
| 02:49PM | Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks |
| 02:40PM | Amgen Inc. -- Moody's: Amgen's BeiGene collaboration will expand geographic reach but reduce cash Moody's |
| 07:38AM | The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance Benzinga |
| 04:53AM | Amgen to Take $2.7 Billion Stake in BeiGene for China Growth Bloomberg |
| 03:01AM | Jobs Report, Exxon, Pinterest, Amgen, U.S. Steel - 5 Things You Must Know Friday TheStreet.com |
| Oct-31-19 05:28PM | Amgen Is Taking A $2.7 Billion Stake In A Chinese Biotech Here's Why Investor's Business Daily |
| 04:00PM | BeiGene Announces Global Strategic Oncology Collaboration with Amgen GlobeNewswire |
| 03:49PM | [video]Amgen Takes $2.7 Billion Stake in BeiGene to Expand Access to China TheStreet.com |
| 07:54AM | Have Insiders Been Selling BeiGene, Ltd. (NASDAQ:BGNE) Shares? Simply Wall St. |
| Oct-30-19 10:00AM | BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy? Zacks |
| Oct-29-19 08:02PM | HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud: Investors Who Suffered Losses Encouraged to Contact Firm GlobeNewswire |
| Oct-28-19 03:30PM | ROSEN, A HIGHLY RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE Business Wire |
| Oct-23-19 04:50PM | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 10:30AM | Were Hedge Funds Right About Dumping BeiGene, Ltd. (BGNE)? Insider Monkey |
| Oct-18-19 03:35PM | SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| Oct-16-19 04:00PM | IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| Oct-15-19 05:13PM | Reata Successfully Completes Neuromuscular Disorder Study Zacks |
| Oct-08-19 03:54PM | Lifshitz & Miller LLP Announces Investigation of Aflac Inc., BeiGene, Ltd., Meredith Corporation, New Relic, Inc., Ollie's Bargain Outlet Holdings, Inc., SmileDirectClub, Inc., and Sonim Technologies, Inc. PR Newswire |
| Oct-07-19 08:05PM | BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud GlobeNewswire |
| 04:00PM | ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| Oct-01-19 07:19PM | Bragar Eagel & Squire, P.C. Is Investigating Tandy Leather Factory, ADTRAN, BeiGene, and Altria Group on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire |
| Sep-30-19 08:04PM | BGNE INVESTOR REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud GlobeNewswire |
| 11:30AM | BGNE LOSS NOTICE: ROSEN, A TOP RANKED LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| 06:00AM | BeiGene Announces Clinical Data on Tislelizumab and Pamiparib Presented at the European Society for Medical Oncology (ESMO) Congress 2019 GlobeNewswire |
| Sep-26-19 06:05PM | BeiGene Announces Clinical Data on Tislelizumab and Pamiparib to Be Presented at the European Society for Medical Oncology (ESMO) Congress 2019 GlobeNewswire |
| Sep-25-19 03:16PM | BGNE LOSSES ALERT: Bernstein Liebhard LLP Shareholders of its Investigation of BeiGene Ltd. PR Newswire |
| 12:12PM | Should You Be Pleased About The CEO Pay At BeiGene, Ltd.'s (NASDAQ:BGNE) Simply Wall St. |
| 09:55AM | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces It Is Investigating Claims Against BeiGene, Ltd. and Encourages Investors With Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Sep-23-19 08:06PM | BGNE INVESTIGATION REMINDER: Hagens Berman Reminds BeiGene, Ltd. (BGNE) Investors of Ongoing Investigation of Possible Securities Fraud GlobeNewswire |
| 06:56PM | BGNE LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE Business Wire |
| Sep-22-19 07:00PM | BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) GlobeNewswire |
| Sep-19-19 09:25PM | ONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE |
| 04:45PM | ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against BeiGene, Ltd. BGNE GlobeNewswire |
| Sep-18-19 10:50AM | ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Sep-17-19 08:02PM | BGNE SHAREHOLDER ALERT: Hagens Berman Reminds Investors in BeiGene, Ltd. (BGNE) of Ongoing Investigation of Possible Securities Fraud GlobeNewswire |
| 12:40PM | SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE |
| Sep-16-19 04:40PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE |
| 04:00PM | Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of BeiGene, Ltd. Investors Business Wire |
| 03:15PM | ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE |
| 01:54PM | INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of BeiGene, Ltd. Investors (BGNE) Business Wire |
| Sep-15-19 03:15PM | BGNE NOTICE, ROSEN, A GLOBALLY RANKED FIRM, Announces Investigation of Securities Claims Against BeiGene, Ltd.; Encourages Investors with Losses over $100K to Inquire - BGNE ACCESSWIRE |
| Sep-14-19 07:22AM | SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE |
| Sep-13-19 10:00PM | Bragar Eagel & Squire, P.C. is Investigating BeiGene, Ltd. (NASDAQ: BGNE) on Behalf of BeiGene Stockholders and Encourages BeiGene Investors to Contact the Firm Business Wire |
| 09:20PM | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of BeiGene, Ltd. - BGNE ACCESSWIRE |
| 05:06PM | ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| 03:00PM | IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE |
| 10:30AM | Glancy Prongay & Murray LLP Announces Investigation on Behalf of BeiGene, Ltd. Investors Business Wire |
| Sep-12-19 09:10PM | SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses in Excess of $50,000 to Contact the Firm ACCESSWIRE |
|
|
|
|
| BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; CC-122, a cereblon modulator; and BGB-3245, an oral small molecule inhibitor of specific BRAF mutations, including B-RAF non-V600 mutations and RAF fusions for various solid tumor indications. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is headquartered in Beijing, the People's Republic of China. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Wang Xiaodong | Chair, Scientific Advisory Brd | Mar 04 | Sale | 157.14 | 5,000 | 785,681 | 0 | Mar 06 08:30 PM | | Huang Jane | CMO, Hematology | Feb 18 | Option Exercise | 29.49 | 1,500 | 44,235 | 1,500 | Feb 20 04:13 PM | | Huang Jane | CMO, Hematology | Feb 18 | Sale | 170.25 | 1,500 | 255,380 | 0 | Feb 20 04:13 PM | | Huang Jane | CMO, Hematology | Jan 21 | Option Exercise | 29.49 | 1,500 | 44,235 | 1,500 | Jan 22 06:59 PM | | Huang Jane | CMO, Hematology | Jan 21 | Sale | 170.69 | 1,500 | 256,042 | 0 | Jan 22 06:59 PM | | OYLER JOHN | Chief Executive Officer | Dec 17 | Sale | 160.62 | 62,259 | 10,000,100 | 0 | Dec 19 04:10 PM | | Huang Jane | CMO, Hematology | Dec 16 | Option Exercise | 29.49 | 1,500 | 44,235 | 1,500 | Dec 18 06:57 PM | | Huang Jane | CMO, Hematology | Dec 16 | Sale | 165.14 | 1,500 | 247,710 | 0 | Dec 18 06:57 PM | | Huang Jane | CMO, Hematology | Nov 18 | Option Exercise | 29.49 | 1,500 | 44,235 | 1,500 | Nov 20 07:19 PM | | Liang Howard | CFO & Chief Strategy Officer | Nov 18 | Option Exercise | 6.50 | 25,000 | 162,500 | 25,000 | Nov 20 07:20 PM | | Huang Jane | CMO, Hematology | Nov 18 | Sale | 194.49 | 1,500 | 291,740 | 0 | Nov 20 07:19 PM | | Liang Howard | CFO & Chief Strategy Officer | Nov 18 | Sale | 194.34 | 25,000 | 4,858,616 | 0 | Nov 20 07:20 PM | | Wu Xiaobin | President & GM China | Nov 15 | Sale | 202.05 | 1,000 | 202,050 | 0 | Nov 18 05:22 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Nov 15 | Sale | 202.05 | 395 | 79,810 | 0 | Nov 18 05:24 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Nov 15 | Sale | 202.05 | 1,496 | 302,267 | 0 | Nov 18 05:24 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Nov 14 | Sale | 193.57 | 2,605 | 504,242 | 395 | Nov 18 05:24 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Nov 14 | Sale | 193.31 | 8,504 | 1,643,880 | 1,496 | Nov 18 05:24 PM | | Chen Timothy Yung-Cheng | Director | Nov 05 | Option Exercise | 41.01 | 4,000 | 164,040 | 4,000 | Nov 06 06:50 PM | | Chen Timothy Yung-Cheng | Director | Nov 05 | Sale | 189.15 | 3,800 | 718,772 | 200 | Nov 06 06:50 PM | | Huang Jane | CMO, Hematology | Nov 04 | Option Exercise | 29.49 | 32,900 | 970,221 | 32,900 | Nov 06 06:51 PM | | Chen Timothy Yung-Cheng | Director | Nov 04 | Option Exercise | 41.01 | 4,000 | 164,040 | 4,000 | Nov 06 06:50 PM | | Chen Timothy Yung-Cheng | Director | Nov 04 | Sale | 190.49 | 4,200 | 800,073 | 0 | Nov 06 06:50 PM | | Huang Jane | CMO, Hematology | Nov 04 | Sale | 190.46 | 32,900 | 6,266,007 | 0 | Nov 06 06:51 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Nov 04 | Sale | 190.00 | 1,000 | 190,000 | 0 | Nov 05 04:22 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Nov 01 | Sale | 170.00 | 1,000 | 170,000 | 0 | Nov 05 04:22 PM | | Wu Xiaobin | President & GM China | Nov 01 | Sale | 180.00 | 1,000 | 180,000 | 0 | Nov 05 04:20 PM | | Huang Jane | CMO, Hematology | Sep 04 | Sale | 129.40 | 82 | 10,611 | 0 | Sep 05 08:15 PM | | Huang Jane | CMO, Hematology | Sep 03 | Sale | 144.45 | 2,862 | 413,420 | 0 | Sep 05 08:15 PM | | Chen Timothy Yung-Cheng | Director | Aug 23 | Option Exercise | 31.59 | 7,900 | 249,561 | 7,900 | Aug 27 04:04 PM | | Chen Timothy Yung-Cheng | Director | Aug 23 | Sale | 144.96 | 8,614 | 1,248,680 | 0 | Aug 27 04:04 PM | | Huang Jane | CMO, Hematology | Aug 12 | Option Exercise | 45.31 | 2,500 | 113,275 | 2,500 | Aug 13 04:47 PM | | Huang Jane | CMO, Hematology | Aug 12 | Sale | 134.74 | 2,500 | 336,855 | 0 | Aug 13 04:47 PM | | Huang Jane | CMO, Hematology | Jul 29 | Option Exercise | 37.30 | 10,130 | 377,834 | 10,130 | Jul 31 04:04 PM | | Huang Jane | CMO, Hematology | Jul 29 | Sale | 134.54 | 10,130 | 1,362,896 | 0 | Jul 31 04:04 PM | | OYLER JOHN | Chief Executive Officer | Jul 08 | Sale | 126.87 | 3,106 | 394,055 | 0 | Jul 09 07:23 PM | | Wang Xiaodong | Chair, Scientific Advisory Brd | Jul 01 | Sale | 126.46 | 4,847 | 612,937 | 0 | Jul 01 08:27 PM | | Huang Jane | CMO, Hematology | Jun 27 | Sale | 124.52 | 430 | 53,542 | 0 | Jul 01 08:30 PM | | Liang Howard | CFO & Chief Strategy Officer | Jun 27 | Sale | 9.47 | 5,876 | 55,653 | 122,317 | Jul 01 08:28 PM | | Liang Howard | CFO & Chief Strategy Officer | May 21 | Option Exercise | 6.50 | 23,200 | 150,800 | 23,200 | May 22 07:03 PM | | Huang Jane | CMO, Hematology | May 21 | Option Exercise | 45.31 | 2,200 | 99,682 | 2,200 | May 22 07:04 PM | | Huang Jane | CMO, Hematology | May 21 | Sale | 130.06 | 2,200 | 286,132 | 0 | May 22 07:04 PM | | Liang Howard | CFO & Chief Strategy Officer | May 21 | Sale | 130.21 | 23,200 | 3,020,860 | 0 | May 22 07:03 PM | | Huang Jane | CMO, Hematology | May 20 | Option Exercise | 45.31 | 300 | 13,593 | 300 | May 22 07:04 PM | | Huang Jane | CMO, Hematology | May 20 | Sale | 130.12 | 300 | 39,036 | 0 | May 22 07:04 PM | | Glazer Donald W. | Director | May 13 | Sale | 125.11 | 15,027 | 1,880,028 | 0 | May 15 03:59 PM | | Liang Howard | CFO & Chief Strategy Officer | May 06 | Option Exercise | 6.50 | 1,800 | 11,700 | 1,800 | May 08 05:53 PM | | Liang Howard | CFO & Chief Strategy Officer | May 06 | Sale | 130.01 | 1,800 | 234,014 | 0 | May 08 05:53 PM | | Wu Xiaobin | President & GM China | May 01 | Sale | 124.52 | 5,955 | 741,546 | 17,365 | May 02 04:08 PM | | OYLER JOHN | Chief Executive Officer | May 01 | Sale | 125.18 | 2,824 | 353,505 | 0 | May 02 04:07 PM | | Huang Jane | CMO, Hematology | Apr 08 | Option Exercise | 29.49 | 14,130 | 416,694 | 14,130 | Apr 10 06:41 PM | | Huang Jane | CMO, Hematology | Apr 08 | Sale | 142.77 | 14,130 | 2,017,315 | 0 | Apr 10 06:41 PM |
|
|
|
|
|
|
